

Amendment to the Claims

This listing of claims will replace all prior versions and listings of claims.

1. (Currently Amended) An isolated antibody or fragment thereof that specifically binds to a protein selected from the group consisting of:
 - (a) ~~a protein consisting of amino acid residues 46 to 373 of SEQ ID NO:2;~~
 - (b) ~~a protein consisting of amino acid residues 23 to 373 of SEQ ID NO:2;~~
 - (c) ~~a protein consisting of amino acid residues 1 to 373 of SEQ ID NO:2;~~
 - (d) ~~a protein consisting of amino acid residues 24 to 373 of SEQ ID NO:2;~~
 - (e) (a) a protein consisting of amino acid residues 85 to 165 of SEQ ID NO:2;
 - (f) (b) a protein consisting of amino acid residues 108 to 121 of SEQ ID NO:2;
 - (g) ~~a protein consisting of a fragment of SEQ ID NO:2, wherein said fragment comprises at least 30 contiguous amino acid residues of SEQ ID NO:2; and~~
 - (h) ~~a protein consisting of a fragment of SEQ ID NO:2, wherein said fragment comprises at least 50 contiguous amino acid residues of SEQ ID NO:2.~~
2. (Original) The antibody or fragment thereof of claim 1 that specifically binds protein (a).
3. (Original) The antibody or fragment thereof of claim 1 that specifically binds protein (b).
- 4-10. (Canceled)
11. (Currently Amended) The antibody or fragment thereof of ~~claim 6~~ claim 2 wherein said protein bound by said antibody or fragment thereof is glycosylated.
12. (Currently Amended) The antibody or fragment thereof of ~~claim 6~~ claim 2 which is a polyclonal antibody.
13. (Currently Amended) The antibody or fragment thereof of ~~claim 6~~ claim 2 which is selected from the group consisting of:
 - (a) a chimeric antibody;
 - (b) a single chain antibody; and

(c) a Fab fragment.

14. (Currently Amended) The antibody or fragment thereof of ~~claim 6~~ claim 2 which is labeled.
15. (Previously Presented) The antibody or fragment thereof of claim 14 wherein the label is selected from the group consisting of:
 - (a) an enzyme; and
 - (b) a fluorescent label.
16. (Currently Amended) The antibody or fragment thereof of ~~claim 6~~ claim 2 wherein said antibody specifically binds to said protein in a Western blot.
17. (Currently Amended) The antibody or fragment thereof of ~~claim 6~~ claim 2 wherein said antibody specifically binds to said protein in an ELISA.
18. (Currently Amended) An isolated cell that produces the antibody or fragment thereof of ~~claim 6~~ claim 2.
19. (Currently Amended) A hybridoma that produces the antibody or fragment thereof of ~~claim 6~~ claim 2.
20. (Currently Amended) A method of detecting VEGF-2 protein in a biological sample comprising:
 - (a) contacting the biological sample with the antibody or fragment thereof of ~~claim 6~~ claim 2; and
 - (b) detecting the VEGF-2 protein in the biological sample.
21. (Withdrawn) The method of claim 20 wherein the antibody or fragment thereof is a polyclonal antibody.
22. (Currently Amended) An isolated antibody or fragment thereof obtained from an animal that has been immunized with a protein selected from the group consisting of:

- (a) a protein comprising the amino acid sequence of amino acid residues 46 to 373 of SEQ ID NO:2;
- (b) a protein comprising the amino acid sequence of amino acid residues 23 to 373 of SEQ ID NO:2;
- (c) a protein comprising the amino acid sequence of amino acid residues 1 to 373 of SEQ ID NO:2;
- (d) a protein comprising the amino acid sequence of amino acid residues 24 to 373 of SEQ ID NO:2;
- (e) (a) a protein comprising the amino acid sequence of amino acid residues 85 to 165 of SEQ ID NO:2;
- (f) (b) a protein comprising the amino acid sequence of amino acid residues 108 to 121 of SEQ ID NO:2;
- (g) a protein comprising the amino acid sequence of at least 30 contiguous amino acid residues of SEQ ID NO:2; and
- (h) a protein comprising the amino acid sequence of at least 50 contiguous amino acid residues of SEQ ID NO:2;

wherein said antibody or fragment thereof specifically binds to said amino acid sequence.

23. (Original) The antibody or fragment thereof of claim 22 obtained from an animal immunized with protein (a).

24. (Original) The antibody or fragment thereof of claim 22 obtained from an animal immunized with protein (b).

25-30. (Canceled)

31. (Original) The antibody or fragment thereof of claim 22 which is a monoclonal antibody.

32. (Original) The antibody or fragment thereof of claim 22 which is selected from the group consisting of:

- (a) a chimeric antibody;
- (b) a polyclonal antibody;

- (c) a single chain antibody; and
- (d) a Fab fragment.

33. (Currently Amended) An isolated monoclonal antibody or fragment thereof that specifically binds to a protein selected from the group consisting of:
- (a) ~~a protein consisting of amino acid residues 46 to 373 of SEQ ID NO:2;~~
 - (b) ~~a protein consisting of amino acid residues 23 to 373 of SEQ ID NO:2;~~
 - (c) ~~a protein consisting of amino acid residues 1 to 373 of SEQ ID NO:2;~~
 - (d) ~~a protein consisting of amino acid residues 24 to 373 of SEQ ID NO:2;~~
 - (e) (a) a protein consisting of amino acid residues 85 to 165 of SEQ ID NO:2;
 - (f) (b) a protein consisting of amino acid residues 108 to 121 of SEQ ID NO:2;
 - (g) ~~a protein consisting of a fragment of SEQ ID NO:2, wherein said fragment comprises at least 30 contiguous amino acid residues of SEQ ID NO:2; and~~
 - (h) ~~a protein consisting of a fragment of SEQ ID NO:2, wherein said fragment comprises at least 50 contiguous amino acid residues of SEQ ID NO:2.~~

34. (Original) The antibody or fragment thereof of claim 33 that specifically binds protein (a).

35. (Original) The antibody or fragment thereof of claim 33 that specifically binds protein (b).

36-42. (Canceled)

43. (Currently Amended) The antibody or fragment thereof of ~~claim 38~~ claim 34 wherein said protein bound by said antibody or fragment thereof is glycosylated.

44. (Currently Amended) The antibody or fragment thereof of ~~claim 38~~ claim 34 which is selected from the group consisting of:

- (a) a chimeric antibody;
- (b) a single chain antibody; and
- (c) a Fab fragment.

45. (Currently Amended) The antibody or fragment thereof of ~~claim 38~~ claim 34 which is labeled.
46. (Previously Presented) The antibody of claim 45 wherein the label is selected from the group consisting of:
- (a) an enzyme; and
 - (b) a fluorescent label.
47. (Currently Amended) The antibody or fragment thereof of ~~claim 38~~ claim 34 wherein said antibody specifically binds to said protein in a Western blot.
48. (Currently Amended) The antibody or fragment thereof of ~~claim 38~~ claim 34 wherein said antibody specifically binds to said protein in an ELISA.
49. (Currently Amended) An isolated cell that produces the antibody or fragment thereof of ~~claim 38~~ claim 34.
50. (Currently Amended) A hybridoma that produces the antibody or fragment thereof of ~~claim 38~~ claim 34.
51. (Currently Amended) A method of detecting VEGF-2 protein in a biological sample comprising:
- (a) contacting the biological sample with the antibody or fragment thereof of ~~claim 38~~ claim 34; and
 - (b) detecting the VEGF-2 protein in the biological sample.
- 52-90. (Canceled)
91. (Currently Amended) A method of inhibiting angiogenesis in a patient comprising administering to the patient the antibody of any one of claims ~~4, 6, 22, 33, 38, 52, 54, 69, 76, or 78~~ 1, 2, 22, 33, or 34.

92. (Currently Amended) A method of inhibiting neovascularization in a patient comprising administering to the patient the antibody of claim ~~1, 6, 22, 33, 38, 52, 54, 69, 76, or 78~~ 1, 2, 22, 33, or 34.
93. (Currently Amended) A method of inhibiting a tumor in a patient comprising administering to the patient the antibody of claim ~~1, 6, 22, 33, 38, 52, 54, 69, 76, or 78~~ 1, 2, 22, 33, or 34.
94. (Currently Amended) A method of inhibiting diabetic retinopathy in a patient comprising administering to the patient the antibody of claim ~~1, 6, 22, 33, 38, 52, 54, 69, 76, or 78~~ 1, 2, 22, 33, or 34.
95. (Currently Amended) A method of inhibiting psoriasis in a patient comprising administering to the patient the antibody of claim ~~1, 6, 22, 33, 38, 52, 54, 69, 76, or 78~~ 1, 2, 22, 33, or 34.
96. (Currently Amended) A method of inhibiting rheumatoid arthritis in a patient comprising administering to the patient the antibody of claim ~~1, 6, 22, 33, 38, 52, 54, 69, 76, or 78~~ 1, 2, 22, 33, or 34.

97-110. (Canceled)